The SGLT2 inhibitor dapagliflozin did not result in a reduced incidence of organ failure or death in patients with cardiometabolic risk factors who were hospitalized with COVID-19, according to the phase III DARE-19* trial. However, this finding does not support discontinuation of SGLT2 inhibitors in COVID-19 patients.
Taking low-strength aspirin at 81 mg dose daily (also known as baby aspirin) appeared to be as effective as a higher dose of 325 mg for secondary prevention in people with established atherosclerotic cardiovascular disease (ASCVD), with no difference in major bleeding outcomes, according to the ADAPTABLE* trial presented at ACC.2.
Use of an interactive web-based system via mobile phones has allowed patients to have a more proactive role in managing their blood pressure (BP) and thus become an expert of their BP, results of a study have shown.
The fractional flow reserve (FFR) approach is no better than angiography-guided strategy in patients with multivessel STEMI* undergoing complete revascularization in the head-to-head FLOWER-MI trial**.
Left atrial appendage occlusion (LAAO) added to usual care led to a reduction in ischaemic stroke or non-cerebral systemic embolism following cardiac surgery among patients with atrial fibrillation (AF), according to results of the LAAOS* III trial.
Treatment with the HMG-CoA reductase inhibitor atorvastatin in critically ill patients with COVID-19 did not significantly reduce the primary composite outcome of venous or arterial thrombosis risk, treatment with extracorporeal membrane oxygenation (ECMO), or mortality vs placebo in the INSPIRATION-S study presented at ACC.21.
Only a small fraction of patients with stable ischaemic heart disease (SIHD) who undergo percutaneous coronary intervention (PCI) in the US meet the inclusion criteria of the ISCHEMIA* trial, according to results of a study presented at SCAI 2021.
New drug applications approved by US FDA as of 01-15 June 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.